AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC trimmed its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 4.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 61,948 shares of the biotechnology company’s stock after selling 3,044 shares during the period. Fisher Asset Management LLC’s holdings in AnaptysBio were worth $2,075,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in ANAB. Frazier Life Sciences Management L.P. increased its stake in AnaptysBio by 140.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after acquiring an additional 1,265,891 shares during the last quarter. Jennison Associates LLC purchased a new stake in shares of AnaptysBio during the 3rd quarter worth about $8,874,000. Victory Capital Management Inc. increased its position in AnaptysBio by 677.9% during the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after purchasing an additional 206,750 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in AnaptysBio by 55.1% in the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after buying an additional 168,813 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in AnaptysBio during the second quarter valued at approximately $1,360,000.

Insiders Place Their Bets

In related news, insider Eric J. Loumeau sold 8,720 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.82, for a total transaction of $347,230.40. Following the sale, the insider now owns 7,020 shares in the company, valued at $279,536.40. This represents a 55.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Dennis Mulroy sold 12,220 shares of AnaptysBio stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. The trade was a 72.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,440 shares of company stock valued at $892,936 in the last quarter. Insiders own 33.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ANAB. HC Wainwright cut their target price on shares of AnaptysBio from $55.00 to $52.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Truist Financial boosted their price objective on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. Guggenheim increased their target price on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Wedbush reissued an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a research report on Thursday, November 14th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of AnaptysBio from $75.00 to $66.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $54.64.

AnaptysBio Price Performance

ANAB opened at $24.96 on Friday. AnaptysBio, Inc. has a 12-month low of $13.96 and a 12-month high of $41.31. The stock has a market capitalization of $759.53 million, a PE ratio of -4.11 and a beta of -0.24. The firm’s fifty day moving average price is $28.13 and its 200 day moving average price is $29.68.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, equities research analysts forecast that AnaptysBio, Inc. will post -6.02 earnings per share for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.